Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Design Therapeutics (DSGN)/b) announced that its management will participate in a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.A live webcast will be accessible via the investors section of the company’s website, and the replay will be archived for at least 30 days.
Details
News Market Reaction – DSGN
On Sep 2, the day this news came out, DSGN closed 2.44% above the previous close. Our momentum scanner recorded 3 alerts for this stock that day. Relative volume reached 2.2x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Announcement date
- September 2, 2026
- Article publication date
- Conference date
- September 9, 2026
- 2026 Cantor Fitzgerald Global Healthcare Conference
- Presentation time
- 2:45 p.m. ET
- Fireside chat in New York
- Webcast archive
- At least 30 days
- Following the presentation
Historical Context
-
RESTORE-FA update accompanied second-quarter results and revised dosing and endpoint plans.
-
Patient dosing began in Phase 1 DT-818 multiple-ascending-dose trial for DM1.
-
Company announced participation in Jefferies healthcare conference fireside chat and webcast.
-
Four-week RESTORE-FA data reported clinical improvements and dose-dependent biomarker activity.
-
Company scheduled webcast to review upcoming RESTORE-FA trial data with investors.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com.The webcast will be archived for at least 30 days following each presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck, THRUST
renee@thrustsc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.